丙型肝炎病毒血清学阳性供体肝脏移植的最新进展
Recent advances in liver transplantation with HCV seropositive donors.
作者信息
Murag Soumya, Dennis Brittany B, Kim Donghee, Ahmed Aijaz, Cholankeril George
机构信息
Department of Medicine, Santa Clara Valley Medical Center, Santa Clara, CA, USA.
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
出版信息
F1000Res. 2019 Dec 30;8. doi: 10.12688/f1000research.20387.1. eCollection 2019.
The paradigm shift from interferon-based to direct-acting antiviral (DAA) therapy for the treatment of hepatitis C virus (HCV) infection has revolutionized the field of liver transplantation. These advances in effective HCV treatment, along with the persistent shortage in available liver grafts, have encouraged investigators to assess the need for adopting more inclusive donor policies. Owing to the poor outcomes following liver transplantation with recurrent HCV infection, liver transplantation using HCV seropositive donors (non-viremic and viremic) had been restricted. However, as a result of the growing supply of HCV seropositive donors from the recent opioid epidemic along with the advent of efficacious DAA therapy to treat HCV recurrence, there has been an increasing trend to use HCV seropositive donors for both HCV seropositive and seronegative recipients. The review aims to discuss recent advances and associated outcomes related to the use of HCV seropositive grafts for liver transplantation.
从基于干扰素的疗法转向直接作用抗病毒（DAA）疗法来治疗丙型肝炎病毒（HCV）感染，这一范式转变彻底改变了肝移植领域。有效的HCV治疗方面的这些进展，以及可用肝脏移植物的持续短缺，促使研究人员评估采用更具包容性的供体政策的必要性。由于复发性HCV感染的肝移植术后效果不佳，使用HCV血清学阳性供体（非病毒血症和病毒血症）进行肝移植一直受到限制。然而，由于近期阿片类药物流行导致HCV血清学阳性供体供应增加，以及有效治疗HCV复发的DAA疗法的出现，使用HCV血清学阳性供体进行肝移植给HCV血清学阳性和血清学阴性受者的趋势日益增加。这篇综述旨在讨论与使用HCV血清学阳性移植物进行肝移植相关的最新进展及相关结果。
Zotero 插件